Gelsolin levels were significantly upregulated in 78% of patients with cervical cancer. Levels were higher in cervical tumor tissues than in the surrounding noncancerous tissues. Gelsolin abundance in the plasma of cervical cancer patients was increased 2.2-fold compared to healthy controls and was significantly different in the early and late stages. Survival and recurrence-free survival rates were significantly higher for the low-expression group. Cancer cells with reduced gelsolin expression exhibited reduced migration and proliferation. The gene discussed is GSN; the disease is uterine cervix neoplasm.